EyePoint Inc (EYPT)

• Market cap: $1.05B
• 1 day: -4.71%
• 5 days: -6.35%
• 1 month: -9.53%
• 3 months: -31.68%
• 6 months: -8.47%
• Year to date: -28.32%
• 1 year: 68.87%
• 5 years: 34.01%
• 10 years: -65.58%
• Sector: Healthcare
• Industry: Biotechnology

About: EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 214